Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment protocol for elderly patients with mantle cell lymphoma (MCL)
2004-003255-39Phase 4Completed
- Sponsor
- Finnish Lymphoma Group
- Start
- Dec 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by Finnish Lymphoma Group. Primary endpoints: Complete response rate, Progression-free survival and 1 more. Started Dec 2004; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2004-003255-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003255-39.